BioCryst Pharmaceuticals Says It Expects To Achieve Full-year Operating Profit In 2024, Approach Quarterly Positive EPS And Positive Cash Flow In 2H Of 2025, And Be Profitable On An EPS Basis, With Positive Cash Flow, For Full Year 2026
Portfolio Pulse from Benzinga Newsdesk
BioCryst Pharmaceuticals announced its financial outlook, expecting to achieve full-year operating profit in 2024, approach quarterly positive EPS and positive cash flow in the second half of 2025, and be profitable on an EPS basis with positive cash flow for the full year 2026.
August 05, 2024 | 11:07 am
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
BioCryst Pharmaceuticals expects to achieve full-year operating profit in 2024, approach quarterly positive EPS and positive cash flow in the second half of 2025, and be profitable on an EPS basis with positive cash flow for the full year 2026.
The announcement of expected profitability and positive cash flow in the coming years is likely to boost investor confidence and positively impact the stock price in the short term.
CONFIDENCE 85
IMPORTANCE 90
RELEVANCE 100